June 2026
Cannabis
What June 2026's 5 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, cannabidiol, CBD, then ranked by relevance.
Research on cannabis in June 2026 is limited and indirect. One rodent study found that a combination of cannabidiol (CBD) and sodium nitroprusside showed sex-dependent prophylactic effects in a schizophrenia model, but CBD alone had limited efficacy. A meta-analysis of psychedelic-assisted psychotherapy for PTSD included one trial of cannabidiol that showed no clear benefit. Overall, the evidence is too sparse and preliminary to draw firm conclusions about cannabis effects in humans.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Cannabis Sativa, religion and society: Historical, medicinal, legal, and sacramental perspectives 2026 | theoretical/review | Unclear | This article reviews historical, medicinal, legal, and religious aspects of Cannabis sativa but does not present new empirical findings on cannabis effects. | |
| Attitudes of Mental Healthcare Professionals Towards the Use of Psychedelics in the Treatment of Substance Use Disorders: A Systematic Review 2026 | systematic review | 966 | Unclear | This systematic review found that mental healthcare professionals hold cautiously optimistic attitudes toward psychedelic-assisted therapy for substance use disorders, but it does not report direct effects of cannabis. |
| Prophylactic efficacy of cannabidiol and sodium nitroprusside in a ketamine model of schizophrenia: sex-dependent effects on positive-like and cognitive impairments 2026 | preclinical rodent study | Mixed | In a ketamine model of schizophrenia, cannabidiol (CBD) alone had limited prophylactic efficacy, but its combination with sodium nitroprusside reduced hyperlocomotion and prevented novel object recognition deficits in both sexes, with superior effects in females. | |
| Psychedelic-Assisted Psychotherapy for the Treatment of PTSD: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | 358 | No effect | In a meta-analysis of psychedelic-assisted psychotherapy for PTSD, a single trial of cannabidiol showed no clear benefit for symptom reduction. |
| Spiritual health and healing in Ethiopia: A scoping review and thematic analysis of beliefs, practices, and gaps in healthcare integration 2026 | scoping review | Unclear | This scoping review on spiritual health in Ethiopia does not address cannabis effects. |
This article reviews historical, medicinal, legal, and religious aspects of Cannabis sativa but does not present new empirical findings on cannabis effects.
theoretical/review
This systematic review found that mental healthcare professionals hold cautiously optimistic attitudes toward psychedelic-assisted therapy for substance use disorders, but it does not report direct effects of cannabis.
systematic review Sample size: 966
In a ketamine model of schizophrenia, cannabidiol (CBD) alone had limited prophylactic efficacy, but its combination with sodium nitroprusside reduced hyperlocomotion and prevented novel object recognition deficits in both sexes, with superior effects in females.
preclinical rodent study
In a meta-analysis of psychedelic-assisted psychotherapy for PTSD, a single trial of cannabidiol showed no clear benefit for symptom reduction.
systematic review and meta-analysis Sample size: 358
This scoping review on spiritual health in Ethiopia does not address cannabis effects.
scoping review
Points of agreement
- Both the rodent study (article 28712) and the meta-analysis (article 28495) indicate that cannabidiol alone has limited or no clear efficacy in the conditions studied (schizophrenia model and PTSD).
- The rodent study (article 28712) and the meta-analysis (article 28495) both suggest that other agents (CBD combined with SNP, or MDMA) may be more promising than CBD alone.
Conflicts
- No direct conflicts, as the studies address different conditions (schizophrenia vs. PTSD) and different designs (preclinical vs. clinical).
Gaps
- No human clinical trials on cannabis or CBD effects published in June 2026 were identified beyond the single CBD trial in the meta-analysis.
- Durability of effects, optimal dosing, and long-term safety of CBD are not addressed.
- Sex-dependent effects of CBD in humans remain unstudied.
- The rodent study (article 28712) is preclinical and requires replication in humans.